What is ARTBIO?
ARTBIO is dedicated to revolutionizing cancer treatment by pioneering a novel category of alpha radioligand therapies (ART). Headquartered in Cambridge, Massachusetts, the company is not only developing these advanced therapeutic agents but also building the necessary infrastructure to ensure their widespread adoption and efficacy. Their work targets the development of a new class of therapies designed to offer more precise and effective cancer care, aiming to significantly improve patient outcomes in a challenging medical field.
How much funding has ARTBIO raised?
ARTBIO has raised a total of $245M across 3 funding rounds:
Angel/Seed
$23M
Series A
$90M
Series B
$132M
Angel/Seed (2023): $23M with participation from F-Prime Capital
Series A (2023): $90M led by F-Prime Capital, Omega Fund Management, and Third Rock Ventures
Series B (2025): $132M supported by B Capital Group, Alexandria, Third Rock Ventures, Qatar Investment Authority, Omega Fund Management, Sofinnova Partners, and F-Prime Capital
Key Investors in ARTBIO
F-Prime Capital
F-Prime Capital is a venture capital firm based in Massachusetts, established in 2002, with a dedicated team of investors, engineers, doctors, and scientists focused on investing in healthcare and technology companies.
Omega Fund Management
Omega Fund Management is a venture capital firm with a primary investment focus on drug discovery and development companies, actively involved in secondary buyouts and academic spinouts, with extensive experience in life science and healthcare investing.
Third Rock Ventures
Third Rock Ventures is a healthcare venture firm founded in 2007, dedicated to discovering, launching, and building companies in disruptive areas of science and medicine to create significant patient value through scientific vision and operational expertise.
What's next for ARTBIO?
With the recent influx of $132M in a major strategic investment, ARTBIO is poised for accelerated growth and the expansion of its therapeutic pipeline. This significant capital infusion, part of its $245M in total financing, will likely fuel further research and development, clinical trials, and the scaling of its operational capabilities. The company's focus on building a comprehensive ecosystem for ART therapies suggests a strategic vision extending beyond drug development to encompass manufacturing, distribution, and patient access, positioning ARTBIO as a key player in the future of precision oncology.
See full ARTBIO company page
